Last reviewed · How we verify

NCT05202340

Factors Affecting Androgen Deprivation Therapy Choice in Prostate Cancer Patients

Completed Last updated 1 June 2023
What this trial tests

trial testing No intervention in Prostate Cancer in 100 participants. Completed in 28 February 2023.

Timeline
7 January 2022
Primary endpoint
31 December 2022
28 February 2023

Quick facts

Lead sponsorChinese University of Hong Kong
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date7 January 2022
Primary completion31 December 2022
Estimated completion28 February 2023
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to investigate possible factors that will affect the choice of androgen deprivation therapy in prostate cancer patients. This is a cross-sectional study performed in Prince of Wales Hospital in Hong Kong. One hundred patients will be recruited for this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05202340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing